In order to raise the awareness of medical and clinical researchers about the importance of epigenetics and promote the basic and transformation research of epigenetics in the medical field, the first Chinese medical epigenetics conference hosted by Beijing Xiehe Hospital of the Chinese Academy of Medical Sciences and Clinical Oncology College of Peking University was solemnly held in Beijing Xiehe academic hall from March 18 to 20, 2016!

Dr. Lu Xianping, the president and chief scientific officer of CHIPSCREEN BIOSCIENCES, was invited to attend the conference and gave a report on the prospect of accurate treatment of Chidamide, a selective histone deacetylase inhibitor in relapsed and refractory lymphoma. Dr. Lu first introduced the anti-tumor mechanism of Chidamide, especially the induction and activation of anti-tumor cellular immune response. Then, the mechanism research and clinical exploration of histone deacetylase inhibitor in treating major blood tumors are elaborated in detail. Based on these studies, a new idea is finally put forward for the future treatment concept of tumor, that is, the combination treatment of epigenetic and other mechanism drugs should be given to the " driving mutation" of tumors, so as to provide a more accurate treatment plan and better long-term survival benefits.

In fact, as early as 2002, the scientific team of CHIPSCREEN BIOSCIENCES carried out exploration and research on epigenetic regulation of complex tumor systems and molecular design of novel epigenetic regulatory agents. Through the company's core technology platform, Chidamide, the first subtype selective histone deacetylase inhibitor in the world, was successfully developed and approved for sale in December 2014, which is also the first original new drug in China to treat peripheral T-cell lymphoma.